Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardamon: Carfilzomib in Multiple Myeloma
NCT02315716Phase 2Active, not recruiting
- Sponsor
- University College London
- Start
- Jun 2015
- Primary completion
- Nov 2019
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in multiple myeloma (MM), sponsored by University College London. Started Jun 2015; status: active, not recruiting.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02315716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02315716.